{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:23:34Z","timestamp":1762507414574},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T00:00:00Z","timestamp":1526515200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T00:00:00Z","timestamp":1526515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Dermatol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1111\/ced.13552","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T04:35:39Z","timestamp":1526618139000},"page":"659-666","source":"Crossref","is-referenced-by-count":7,"title":["Intravenous immunoglobulins in dermatology. Part 2: clinical indications and outcomes"],"prefix":"10.1093","volume":"43","author":[{"given":"E.","family":"Forbat","sequence":"first","affiliation":[{"name":"Chelsea and Westminster Hospital; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. R.","family":"Ali","sequence":"additional","affiliation":[{"name":"Dermatological Surgery and Laser Unit; St John's Institute of Dermatology; Guy's Hospital Cancer Centre; Guy's and St Thomas\u2019 NHS Foundation Trust; Great Maze Pond London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Al-Niaimi","sequence":"additional","affiliation":[{"name":"Dermatological Surgery and Laser Unit; St John's Institute of Dermatology; Guy's Hospital Cancer Centre; Guy's and St Thomas\u2019 NHS Foundation Trust; Great Maze Pond London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,5,17]]},"reference":[{"key":"10.1111\/ced.13552-BIB0001|ced13552-cit-0001","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10875-017-0383-9","article-title":"Evaluation of the safety, tolerability, and pharmacokinetics of Gammaplex(\u00ae) 10% versus Gammaplex(\u00ae) 5% in subjects with primary immunodeficiency","volume":"37","author":"Wasserman","year":"2017","journal-title":"J Clin Immunol"},{"key":"10.1111\/ced.13552-BIB0002|ced13552-cit-0002","unstructured":"Department of Health Clinical guidelines for immunoglobulin use, second edition update http:\/\/www.igd.nhs.uk\/wp-content\/uploads\/2016\/04\/dh_129666.pdf"},{"key":"10.1111\/ced.13552-BIB0003|ced13552-cit-0003","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/jdv.13725","article-title":"European guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology","volume":"30","author":"Enk","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/ced.13552-BIB0004|ced13552-cit-0004","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1111\/ced.13552-BIB0005|ced13552-cit-0005","first-page":"397","article-title":"The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: a 4-year follow-up study","volume":"30","author":"Kampylafka","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1111\/ced.13552-BIB0006|ced13552-cit-0006","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/archdischild-2014-306427","article-title":"Acute and late coronary outcomes in 1073 patients with Kawasaki disease with and without intravenous \u03b3-immunoglobulin therapy","volume":"100","author":"Lin","year":"2015","journal-title":"Arch Dis Child"},{"key":"10.1111\/ced.13552-BIB0007|ced13552-cit-0007","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3349\/ymj.2014.55.5.1260","article-title":"Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease","volume":"55","author":"Lim","year":"2014","journal-title":"Yonsei Med J"},{"key":"10.1111\/ced.13552-BIB0008|ced13552-cit-0008","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3390\/ijms17030278","article-title":"Critical overview of the risk scoring systems to predict non-responsiveness to intravenous immunoglobulin in Kawasaki syndrome","volume":"17","author":"Rigante","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1111\/ced.13552-BIB0009|ced13552-cit-0009","first-page":"CD004000","article-title":"Intravenous immunoglobulin for the treatment of Kawasaki disease in children","author":"Oates-Whitehead","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/ced.13552-BIB0010|ced13552-cit-0010","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/sj.bmt.1703109","article-title":"A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation","volume":"28","author":"Winston","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1111\/ced.13552-BIB0011|ced13552-cit-0011","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","article-title":"A randomized double-blind trial of intravenous immunoglobulin for pemphigus","volume":"60","author":"Amagai","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/ced.13552-BIB0012|ced13552-cit-0012","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/ajd.12422","article-title":"IVIG therapy in pemphigus vulgaris has corticosteroid-sparing and immunomodulatory effects","volume":"57","author":"Svecova","year":"2016","journal-title":"Australas J Dermatol"},{"key":"10.1111\/ced.13552-BIB0013|ced13552-cit-0013","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.4081\/dr.2015.5804","article-title":"Efficacy of intravenous immunoglobulin monotherapy in patients with cutaneous lupus erythematosus: results of proof-of-concept study","volume":"7","author":"Ky","year":"2015","journal-title":"Dermatol Rep"},{"key":"10.1111\/ced.13552-BIB0014|ced13552-cit-0014","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1542\/peds.112.6.1430","article-title":"Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature","volume":"112","author":"Metry","year":"2003","journal-title":"Pediatrics"},{"key":"10.1111\/ced.13552-BIB0015|ced13552-cit-0015","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2012.10965.x","article-title":"The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"167","author":"Huang","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1111\/ced.13552-BIB0016|ced13552-cit-0016","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3899\/jrheum.140833","article-title":"IVIG may be an effective therapy for refractory, active diffuse cutaneous scleroderma","volume":"42","author":"Poelman","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1111\/ced.13552-BIB0017|ced13552-cit-0017","first-page":"151","article-title":"A randomized, double-blind, placebo-controlled tria: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis","volume":"31","author":"Takehara","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1111\/ced.13552-BIB0018|ced13552-cit-0018","first-page":"45","article-title":"Scleromyxedema: a case clinically and histologically responsive to intravenous immunoglobulin","volume":"7","author":"Caudill","year":"2014","journal-title":"J Clin Aesthetic Dermatol"},{"key":"10.1111\/ced.13552-BIB0019|ced13552-cit-0019","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000356469","article-title":"Scleromyxedema with subcutaneous nodules: successful treatment with thalidomide and intravenous immunoglobulin","volume":"5","author":"Dolenc-Volj\u010d","year":"2013","journal-title":"Case Rep Dermatol"},{"key":"10.1111\/ced.13552-BIB0020|ced13552-cit-0020","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1111\/pde.12360","article-title":"Corticosteroid-resistant bullous pemphigoid in infancy: treatment with intravenous immunoglobulin","volume":"31","author":"Ister","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"10.1111\/ced.13552-BIB0021|ced13552-cit-0021","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/1874312901409010077","article-title":"Intravenous immune globulin in amyopathic dermatomyositis - report of two cases and review of the literature","volume":"9","author":"Cafardi","year":"2015","journal-title":"Open Rheumatol J"},{"key":"10.1111\/ced.13552-BIB0022|ced13552-cit-0022","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1081-1206(10)62802-5","article-title":"High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome","volume":"81","author":"Wakim","year":"1998","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1111\/ced.13552-BIB0023|ced13552-cit-0023","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2133.1998.02033.x","article-title":"Intravenous immunoglobulin in autoimmune chronic urticaria","volume":"138","author":"O'Donnell","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1111\/ced.13552-BIB0024|ced13552-cit-0024","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1111\/j.1365-2230.2009.03374.x","article-title":"Solar urticaria successfully treated with intravenous immunoglobulin","volume":"34","author":"Hughes","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/ced.13552-BIB0025|ced13552-cit-0025","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1089\/thy.1994.4.399","article-title":"Pretibial myxedema and high-dose intravenous immunoglobulin treatment","volume":"4","author":"Antonelli","year":"1994","journal-title":"Thyroid"},{"key":"10.1111\/ced.13552-BIB0026|ced13552-cit-0026","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jaad.2015.03.047","article-title":"Intravenous immunoglobulin for treatment of dermatomyositis-associated dystrophic calcinosis","volume":"73","author":"Galimberti","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/ced.13552-BIB0027|ced13552-cit-0027","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/s10165-011-0534-4","article-title":"Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial","volume":"22","author":"Miyasaka","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1111\/ced.13552-BIB0028|ced13552-cit-0028","first-page":"821812","article-title":"A case of Kawasaki disease with coronary aneurysm responding to the 4th IVIG treatment","volume":"2014","author":"Kim","year":"2014","journal-title":"Case Rep Cardiol"},{"key":"10.1111\/ced.13552-BIB0029|ced13552-cit-0029","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/art.20195","article-title":"Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study","volume":"50","author":"Levy","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1111\/ced.13552-BIB0030|ced13552-cit-0030","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/pde.12481","article-title":"Mycoplasma-associated Stevens-Johnson syndrome in children: retrospective review of patients managed with or without intravenous immunoglobulin, systemic corticosteroids, or a combination of therapies","volume":"31","author":"Ahluwalia","year":"2014","journal-title":"Pediatr Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fced.13552","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ced.13552\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:46:23Z","timestamp":1676385983000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/43\/6\/659\/6597271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,17]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,8]]}},"URL":"https:\/\/doi.org\/10.1111\/ced.13552","archive":["Portico"],"relation":{},"ISSN":["0307-6938"],"issn-type":[{"value":"0307-6938","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5,17]]}}}